In addition to binding to CD155, TIGIT can bind to CD112, and both receptor-ligand interactions inhibit NK cytotoxicity directly through the ITIM motif, which inhibits the NK-mediated killing of tumor cells [64]. Here, TIGIT is linked to neoplasm.